In this issue:
- Early detection of NSCLC
- Survival outcomes: Surgery vs surveillance for ground glass nodules
- Futile treatment before death
- Lung cancer incidence in responders post 9/11
- Risk of recurrence after PTNB
- Osimertinib plus chemotherapy in EGFR-mutated NSCLC
- Tarlatamab for SCLC:
– As monotherapy
– Combined with a PD-L1 inhibitor
- Adagrasib vs docetaxel in KRAS-mutated NSCLC
- SCLC: After progression on chemoimmunotherapy
Please login below to download this issue (PDF)